Infectious Bronchitis Virus (ibv) Patents (Class 424/222.1)
-
Patent number: 11224649Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.Type: GrantFiled: October 28, 2019Date of Patent: January 18, 2022Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Annika Kraemer-Kuehl, Hans-Christian Philipp
-
Patent number: 11020475Abstract: Disclosed is cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) prepared by infecting cells with severe acute respiratory syndrome coronavirus and then adapting the severe acute respiratory syndrome coronavirus to a temperature from 37° C. to 22° C. in a step by step manner. Further, a vaccine containing the cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) is disclosed.Type: GrantFiled: October 26, 2020Date of Patent: June 1, 2021Assignee: The Industry & Academic Cooperation in Chungnam National University (IAC)Inventors: Sang-Heui Seo, Yun-Yueng Jang
-
Patent number: 9492548Abstract: The present invention pertains to an emulsion comprising an aqueous phase and an oily phase, the aqueous phase containing a non-live medicinal substance, wherein the aqueous phase comprises at least 30% w/w sugar. The invention also pertains to a method to shield a medicinal substance present in an aqueous phase emulsified with an oily phase, from interaction with the oily phase, and to a vaccine comprising as an antigen a killed micro-organism or a subunit of a micro-organism, the antigen being present in an aqueous phase that is dispersed in an oily phase, wherein the aqueous phase comprises at least 30% w/w sugar.Type: GrantFiled: December 11, 2013Date of Patent: November 15, 2016Assignee: Intervet Inc.Inventors: Erwin Mombarg, Theodorus Jansen, Henricus Johannes Maria Jagt
-
Publication number: 20150086590Abstract: A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.Type: ApplicationFiled: February 19, 2013Publication date: March 26, 2015Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Ryuichi Sakamoto, Masashi Sakaguchi
-
Patent number: 8828407Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.Type: GrantFiled: July 5, 2010Date of Patent: September 9, 2014Assignee: The Pirbright InstituteInventors: Paul Britton, Erica Bickerton, Maria Armesto
-
Publication number: 20140199345Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these methods.Type: ApplicationFiled: May 25, 2012Publication date: July 17, 2014Inventors: Carla Christina Schrier, Simon Ilg
-
Publication number: 20140193457Abstract: The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides.Type: ApplicationFiled: May 25, 2012Publication date: July 10, 2014Inventors: Carla Christina Schrier, Simon ILG
-
Publication number: 20140127264Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.Type: ApplicationFiled: March 1, 2012Publication date: May 8, 2014Inventors: Hèélne Verheije, Carla Christina Schrier
-
Publication number: 20120321663Abstract: A method for preparing a vaccine composition to be implemented in a locally administered treatment for avian viral disease, includes at least the step of: a) extemporaneously mixing a vaccine, including at least one live virus selected from a virus belonging to one or more strains of the avian disease, with an adjuvant diluent (DA), characterized in that the adjuvant diluent is a continuous aqueous phase oil-in-water emulsion or oil-in-water microemulsion.Type: ApplicationFiled: March 15, 2011Publication date: December 20, 2012Applicant: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPICInventors: Francois Bertrand, Sebastien Deville, Laurent Dupuis
-
Publication number: 20120121644Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.Type: ApplicationFiled: July 27, 2010Publication date: May 17, 2012Inventor: Eng-Hong Lee
-
Publication number: 20110305726Abstract: The present invention relates to infectious bronchitis (IB) viruses derived from a recently identified genotype of IB virus known as IB-QX, or from viruses that are genetically related to IB-QX, herein referred to as IB-QX-like viruses. The IB viruses of the invention may be live and attenuated or inactivated. Live, attenuated IB viruses of the invention may be produced by serial passaging of an IB-QX-like virus. The IB viruses of the invention are useful for, inter alia, vaccines against IB-QX and IB-QX-like viruses. Heretofore, known vaccine strains of IB viruses have proven insufficient to protect against infectious bronchitis caused by IB-QX and IB-QX-like viruses.Type: ApplicationFiled: August 7, 2009Publication date: December 15, 2011Applicant: Wyeth LLCInventors: Harmen Jacob Geerligs, Cindy Aleida Maria Meinders, Geert Jan Boelm, Bastiana Geertruida Elisabeth Stuurman
-
Publication number: 20110268762Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes encoding avian influenza virus. The invention also provides methods and apparatus for use in such administration.Type: ApplicationFiled: March 25, 2011Publication date: November 3, 2011Inventors: Haroldo Toro, De-Chu C. Tang, Kent R. Van Kampen
-
Publication number: 20110223195Abstract: The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian species and persistence of the vaccine avian tissues.Type: ApplicationFiled: September 4, 2009Publication date: September 15, 2011Applicant: CEVA SANTE ANIMALE SAInventors: Yannick Gardin, Vilmos Palya, Sylvain Comte
-
Patent number: 7951781Abstract: Embodiments include compositions and methods for lower the surface tension of a liquid-air interface by contacting such interface with all or part of a PLUNC polypeptide.Type: GrantFiled: November 2, 2007Date of Patent: May 31, 2011Assignee: University of Iowa Research FoundationInventors: Paul B. McCray, Jr., Lokesh Gakhar, Rama K. Mallampalli, Subramanian Ramaswamy, Jennifer Bartlett
-
Publication number: 20100150958Abstract: The invention relates to new vaccine compositions for vaccinating birds.Type: ApplicationFiled: November 18, 2009Publication date: June 17, 2010Applicant: VECTOGEN PTY LTD.Inventor: Michael Sheppard
-
Publication number: 20100062019Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: ApplicationFiled: September 10, 2009Publication date: March 11, 2010Inventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
-
Publication number: 20100003279Abstract: A purpose of the present invention is to provide a vaccine for in ovo inoculation effective for prevention of any fowl viral diseases. A fowl vaccine for in ovo inoculation with high efficacy in view of safety as well wherein, by holding such live viruses on a virus-adsorbing agent through adsorption that have been difficult for practical usage as a vaccine for in ovo inoculation, viral growth in embryonated chicken eggs after in ovo inoculation is retarded to thereby reduce pathogenicity of the viruses to embryo to avoid reduction in hatching rate and to alleviate severity in clinical symptoms after hatching. A virus-adsorbing agent to be used in the vaccine includes an aluminum compound such as aluminum hydroxide gel, potassium alum and the like.Type: ApplicationFiled: December 21, 2006Publication date: January 7, 2010Applicant: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Ohta Hideyuki, Shinsuke Ezoe, Kenichi Yamazaki, Toru Kawai
-
Publication number: 20090041852Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.Type: ApplicationFiled: March 15, 2007Publication date: February 12, 2009Applicant: UNIVERSITEIT GENTInventors: Jean Paul Remon, Chris Vervaet, Evy Corbanie
-
Patent number: 7445785Abstract: The present invention provides a vaccine for use in the protection of poultry against infectious bronchitis comprising an attenuated infectious bronchitis virus (IBV) and a pharmaceutical acceptable carrier or diluent, characterized in that the attenuated IBV comprises a heterologous spike gene. Such a vaccine is based on IBV strain Beaudette that is able to express a spike gone derived from a different IBV strain. The vaccines provided by the present invention also allow the administration via the in ovo route.Type: GrantFiled: March 3, 2004Date of Patent: November 4, 2008Assignees: Intervet International B.V., Institute for Animal HealthInventors: David Cavanagh, Paul Britton, Ian Tarpey
-
Patent number: 7291342Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.Type: GrantFiled: May 17, 2004Date of Patent: November 6, 2007Assignee: Intervet International B.V.Inventors: Lillian Melson, Faris Jirjis
-
Patent number: 7192588Abstract: The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.Type: GrantFiled: June 10, 2002Date of Patent: March 20, 2007Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Gilad Gallili, Norbert Frydman
-
Patent number: 7037506Abstract: The present invention provides a vaccine accelerator factor (VAF) which is an in ovo nucleotide immuno-stimulant. The VAF contains one or more DNA constructs, each having a DNA molecule and a vector. Each of the DNA molecule contains one or more genes or gene fragments, each encoding an antigenic peptide of an avian virus. The VAF is preferably administered to the amniotic fluid of an egg after being fertilized for about 17–19 days. The VAF can be co-administered with a viral vaccine containing one or more attenuated or inactive avian viruses. Alternatively, the VAF can be administered prior to the administration of the viral vaccine, which is administered at hatch or post-hatch. The VAF stimulates and accelerate a protective immune response of a viral vaccine.Type: GrantFiled: May 6, 2003Date of Patent: May 2, 2006Assignee: Schweltzer Chemical Corporation Ltd.Inventor: Tsun Yung Kuo
-
Publication number: 20040265339Abstract: Embodiments of the present invention generally relate to a novel attenuated infectious bronchitis virus (IBV) of GA-98 isolate. Further, other embodiments of the present invention generally relate to methods of immunizing avian against an infectious bronchitis virus. As well, further embodiments relate to method of making a vaccine and/or immunogenic composition for protecting avian, such as poultry, from an infectious bronchitis virus of strain GA-98.Type: ApplicationFiled: May 17, 2004Publication date: December 30, 2004Inventors: Lillian Melson, Faris F. Jirjis
-
Publication number: 20020081316Abstract: The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.Type: ApplicationFiled: June 14, 2001Publication date: June 27, 2002Inventors: Mark D. Cochran, Stephanie M. Cook, Martha A. Wild
-
Patent number: 6340464Abstract: Vaccine adjuvants comprising a liquid medium contain polymers with anionic constitutive repeating units and hydrophobic constitutive repeating units. Advantageously, the adjuvants are aqueous solutions of partially esterified polyacrylic acids. The novel adjuvants are highly stable, effective and have a relatively low level of local toxicity. Further, vaccines comprising such adjuvants and a process for producing them are described.Type: GrantFiled: September 3, 1997Date of Patent: January 22, 2002Assignee: American Cyanamid CompanyInventors: Luuk Hilgers, Michel Strebelle
-
Patent number: 6299874Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.Type: GrantFiled: July 11, 2000Date of Patent: October 9, 2001Assignee: University of ArkansasInventors: Craig E. Whitfill, John A. Thoma, Tommy L. Fredericksen, Julius K. Tyczkowski, J. Paul Thaxton, Jr.
-
Patent number: 6183753Abstract: This invention provides a recombinant herpesvirus of turkeys-Marek's disease virus chimera comprising a herpesvirus of turkeys unique long viral genome region and a Marek's disease virus unique short viral genome region.Type: GrantFiled: February 21, 1997Date of Patent: February 6, 2001Assignee: Schering-Plough Veterinary Corp.Inventors: Mark D. Cochran, Martha A. Wild, Barbara J. Winslow